Immuno-oncology and personalized medicine have sparked a new era in cancer research but working with a global patient base can be challenging. Together, we can shape and advance your complex trial by leveraging global, industry-leading labs, Cerba HealthCare patient databases, and our network of scientific experts spanning five continents. This intelligence — along with custom assays and on-target protocol advice — accelerates your program to market.
27,258 Patients screened
5209 Sites
55 Countries
Enhance your research with patient- and science-driven insight
Opportunities for finding proper treatments for both solid tumors and onco-hematological malignancies have never been better. Breakthroughs such as CAR-T cell therapies, checkpoint inhibitors, and combination therapies are rapidly earning FDA approval. With nearly infinite options in specificity and design, many more immune-based therapies are entering the clinical research funnel.
Nonetheless, clinical trial challenges remain. Key drivers include toxicity management, efficacy analysis, and follow-up. Parameters such as tissue distribution, tumor addiction, and surface density must be considered in predicting safety profiles.
The problem of finding proper resources to accomplish your studies compounds these hurdles. With over 35 years of experience, Cerba Research is a leader in oncology clinical trials. Our global solutions comprise a wide range of assays required at various stages of your trial.
Dominique Slaets
Dominique, who holds a PhD in pharmaceutical sciences, joined Cerba HealthCare in 2012 as assistant head of the hematology department. Her specialization in electrophoresis and immunofixation for multiple myeloma trials resulted in the implementation of several IF reflex assays for teasing out monoclonal antibody interferences. In May 2017, she joined Cerba Research as a principal scientist.
Renaud Burrer, PhD
Renaud holds a PhD in virology & immunology and has vast experience in oncology and multiplex immunohistochemistry. Formerly head of R&D at Histalim, he became interim chief scientific officer at Cerba Research in 2019.
Benefit from Cerba Research integrated immune therapy and central laboratory services to evaluate:
Of all our Phase I through Phase IV studies, from translational research to clinical through commercialization, over 50% are oncology trials. Immuno-oncology is progressing rapidly. Talk to us about how we stay current and how we can apply our scientific expertise and state-of-the-art technologies to assist you, including:
| Method | Application |
|---|---|
| Flow cytometry | Immunophenotyping and pharmacokinetics |
| Immunohistochemistry | Target presence and stratification |
| Quantitative PCR | CAR-T cell monitoring Vector copy number analysis (VCN) |
| PCR-based long-term safety testing | Replication competent lentivirus (RCL) screening |
| Immunoassays — ELISA and Meso Scale Discovery (MSD) | Toxicity (cytokine release syndrome) |
| Electrophoresis | Multiple myeloma monitoring |
| Sequencing | Minimal residual disease (MRD) monitoring Patient stratification |